Related Experiment Video
Updated: Apr 21, 2026
12:52
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
15.5K
Galectin-1 and immune suppression during radiotherapy.
James W Welsh1, Steven N Seyedin2, Maria Angelica Cortez2
1Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. jwelsh@mdanderson.org.
Summary
Radiotherapy triggers galectin-1 (Gal-1) secretion, leading to T-cell loss. Inhibiting Gal-1 with shRNA reduces these effects, potentially improving cancer treatment outcomes by preventing radiation-induced lymphopenia.
Area of Science:
- Oncology
- Immunology
Background:
- Radiotherapy is a cornerstone of cancer treatment.
- Radiotherapy can cause side effects, including lymphopenia (low lymphocyte count).
- Galectin-1 (Gal-1) is implicated in immune suppression during cancer therapy.
Purpose of the Study:
- To investigate the role of galectin-1 (Gal-1) in radiotherapy-induced lymphopenia.
- To evaluate the efficacy of Gal-1 inhibition in mitigating these adverse effects.
Main Methods:
- Tumor models treated with radiotherapy.
- Assessment of galectin-1 (Gal-1) secretion levels.
- Evaluation of CD8(+) T-cell apoptosis and lymphopenia.
- Utilized galectin-1 (Gal-1) shRNA to inhibit Gal-1 expression.
Main Results:
- Radiotherapy significantly increased galectin-1 (Gal-1) secretion by tumors.
- Elevated Gal-1 levels correlated with increased CD8(+) T-cell apoptosis and lymphopenia.
- Gal-1 shRNA treatment substantially decreased these radiotherapy-induced effects.
Conclusions:
- Galectin-1 (Gal-1) plays a critical role in mediating radiotherapy-induced lymphopenia.
- Inhibition of Gal-1 presents a promising strategy to overcome radiation-induced T-cell loss.
- Targeting Gal-1 may enhance the clinical efficacy of radiotherapy by preserving immune function.
Related Concept Videos
01:15Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
01:27Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K